# Natural Alternatives International, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Natural Alternatives International, Inc). ## Overview Natural Alternatives International, Inc. manufactures private-label nutritional supplements for brands that sell vitamins, minerals, herbs, and other health products to consumers in the U.S. and abroad. It also monetizes its beta-alanine intellectual property through CarnoSyn®, SR CarnoSyn®, and TriBsyn™ raw material sales, licensing, and royalty arrangements. ## Products & services • Private-label contract manufacturing of nutritional supplements • Vitamins, minerals, herbal and other health products • Beta-alanine raw material sales (CarnoSyn® / SR CarnoSyn®) • TriBsyn™ beta-alanine product sales • Patent, trademark licensing and royalty revenue - **Private-label contract manufacturing** (88%) — Manufacturing of finished nutritional supplement products for third-party brands under customer specifications. - **Patent and trademark licensing** (12%) — Licensing and royalty income tied to the company's beta-alanine intellectual property and trademarks. - Private-label contract manufacturing of nutritional supplements - Vitamins, minerals, herbal and other health products - Beta-alanine raw material sales (CarnoSyn® / SR CarnoSyn®) - TriBsyn™ beta-alanine product sales - Patent, trademark licensing and royalty revenue ## Customers The company sells primarily to private-label brands and distributors that market supplements and health products to end consumers. Management says revenue has historically depended on two or three large customers, so order timing, new product launches, and customer marketing plans can materially swing results. - **Private-label supplement brands** (primary) — Buy contract manufacturing for vitamins, minerals, herbs, and other nutritional supplements to sell under their own labels. - **Health care product marketers** (primary) — Outsource production and packaging of consumer health products where formulation quality and supply reliability matter. - **Beta-alanine ingredient buyers** (secondary) — Purchase CarnoSyn® or TriBsyn™ raw material for sports nutrition, wellness, healthy aging, and medical foods. - **Licensees and royalty partners** (secondary) — Use the company's patents, trademarks, and trade names in exchange for licensing and royalty payments. - Private-label supplement brands that outsource formulation and manufacturing - Health product marketers seeking encapsulation, tablets, powders, and packaging - Customers buying beta-alanine ingredients for sports nutrition and wellness products - Licensees and distributors using CarnoSyn® / TriBsyn™ under IP agreements - Large customers matter because order timing can move quarterly revenue ## Geography The company serves consumers both within and outside the U.S., but the filings provided do not disclose a country revenue split. It operates a wholly owned manufacturing subsidiary in Manno, Switzerland, which gives it a non-U.S. production footprint and exposure to cross-border supply chain, tariff, and foreign exchange effects. - U.S. is the core market for contract manufacturing and ingredient sales - International sales are part of the customer base, but not separately disclosed - Swiss subsidiary in Manno supports manufacturing, warehousing, and distribution - Cross-border sourcing and shipping create tariff and supply chain exposure - Foreign exchange can affect reported results through the Swiss operation ## Strategy Management is focused on diversifying away from a small customer base while improving utilization of its certified facilities. It is also pushing beta-alanine commercialization through raw material sales, new distribution channels, and licensing to broaden revenue sources and reduce dependence on contract manufacturing alone. - **Customer diversification** (short-term) — Reduces dependence on two or three large buyers and lowers order-timing volatility. - **Beta-alanine commercialization** (medium-term) — Creates higher-margin IP-linked revenue streams beyond contract manufacturing. - **Operational efficiency** (short-term) — Better utilization and cost control can improve profitability in a low-margin manufacturing model. - Add quality-oriented private-label customers to reduce concentration risk - Improve factory utilization to lift gross profit and operating leverage - Expand CarnoSyn® and TriBsyn™ commercialization across new channels - Grow royalty and license income from the patent estate - Control costs and business risks to improve profitability ## Risks The biggest company-specific risk is customer concentration, since a few private-label accounts can materially affect sales and quarterly timing. The business is also exposed to tariffs, supply chain disruption, foreign exchange, and geopolitical instability, while the contract manufacturing model remains sensitive to raw material availability, customer demand, and rebate estimates. - **Customer concentration** [high] — Largest private-label customer represented 31% of total net sales in the six months ended Dec. 31, 2025. - **Tariffs and trade duties** [medium] — The company says tariffs can affect its ability to adjust prices and forecast costs on time. - **Geopolitical instability** [medium] — Conflict in Ukraine and the Middle East may disrupt supply chains and energy prices. - **Foreign exchange volatility** [medium] — The Swiss subsidiary creates translation and transaction exposure. - Heavy dependence on a few customers can swing revenue and margins - Tariffs can raise input costs and complicate customer pricing - Supply chain disruptions can limit raw material availability and shipments - Geopolitical instability can affect logistics, energy costs, and markets - Foreign exchange can hurt results from the Swiss subsidiary ## Accounting Revenue recognition is a key judgment area because the company uses customer contracts that may include volume rebates, and management must estimate future sales to measure those rebates. Quarterly results can also be volatile because customer ordering patterns, raw material availability, and licensing revenue timing can shift revenue between periods. - **Revenue recognition and volume rebates** — Net revenue and gross margin - **Quarterly seasonality and order timing** — Comparability of quarterly results - **Foreign currency translation** — Reported earnings and equity - Volume rebate estimates affect net revenue and can change with customer orders - Customer order timing creates quarter-to-quarter revenue volatility - Licensing and royalty revenue can fluctuate with product sales and agreements - Foreign subsidiary translation affects reported earnings and equity - Lease and depreciation expense matter because the company operates manufacturing facilities --- *Last updated: 2026-04-28T20:28:12.184672+00:00*